Cargando…
Drug Development for Pediatric Populations: Regulatory Aspects
Pediatric aspects are nowadays integrated early in the development process of a new drug. The stronger enforcement to obtain pediatric information by the regulatory agencies in recent years resulted in an increased number of trials in children. Specific guidelines and requirements from, in particula...
Autores principales: | Zisowsky, Jochen, Krause, Andreas, Dingemanse, Jasper |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967144/ https://www.ncbi.nlm.nih.gov/pubmed/27721363 http://dx.doi.org/10.3390/pharmaceutics2040364 |
Ejemplares similares
-
Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021) -
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022) -
Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
por: Burgert, Lydia, et al.
Publicado: (2020) -
Confidence and Prediction Intervals for Pharmacometric Models
por: Kümmel, Anne, et al.
Publicado: (2018) -
Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
por: Keunecke, Anne, et al.
Publicado: (2020)